UP­DAT­ED Dew­point nabs ex-Sanofi CEO Brandi­court and Bay­er VC chief Eck­hardt for board

Bay­er-part­nered Dew­point Ther­a­peu­tics is adding a pair of big-name phar­ma vets as it looks to make drugs tar­get­ing bio­mol­e­c­u­lar con­den­sates a re­al­i­ty.

The Boston biotech will add for­mer Sanofi CEO Olivi­er Brandi­court and the head of Bay­er’s ven­ture arm, Jür­gen Eck­hardt, to its board. Though both MDs, the pair has held long ca­reers on the busi­ness side of the in­dus­try, which is where their in­sight will be need­ed most, said Dew­point CEO Amir Nashat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER